MA28689B1 - Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese - Google Patents

Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese

Info

Publication number
MA28689B1
MA28689B1 MA29573A MA29573A MA28689B1 MA 28689 B1 MA28689 B1 MA 28689B1 MA 29573 A MA29573 A MA 29573A MA 29573 A MA29573 A MA 29573A MA 28689 B1 MA28689 B1 MA 28689B1
Authority
MA
Morocco
Prior art keywords
pyrrozolotriazine
angiogenesis
treatment
diseases associated
hyperproliferative disorders
Prior art date
Application number
MA29573A
Other languages
English (en)
Inventor
Catherine Brennan
Karl Miranda
Brent Chandler
Barton Phillips
Jianmei Fan
Michael Brands
Andrea Mcclure
Benjamin Jones
Wenlang Fu
Donald Bierer
Steven Magnuson
Harold C E Kluender
Julie A Dixon
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28689(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA28689B1 publication Critical patent/MA28689B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA29573A 2004-06-03 2006-12-28 Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese MA28689B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
MA28689B1 true MA28689B1 (fr) 2007-06-01

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29573A MA28689B1 (fr) 2004-06-03 2006-12-28 Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese

Country Status (30)

Country Link
US (3) US7563791B2 (fr)
EP (1) EP1765823B1 (fr)
JP (1) JP4958772B2 (fr)
KR (1) KR101235602B1 (fr)
CN (1) CN1993361B (fr)
AR (1) AR049138A1 (fr)
AT (1) ATE462708T1 (fr)
AU (1) AU2005252217B2 (fr)
BR (1) BRPI0510848A (fr)
CA (1) CA2569396C (fr)
DE (1) DE602005020293D1 (fr)
EC (1) ECSP067043A (fr)
ES (1) ES2342722T3 (fr)
GT (1) GT200500137A (fr)
HN (1) HN2005000255A (fr)
IL (1) IL179264A0 (fr)
MA (1) MA28689B1 (fr)
MX (1) MX279139B (fr)
MY (1) MY145077A (fr)
NO (1) NO20070049L (fr)
NZ (1) NZ551742A (fr)
PE (1) PE20060243A1 (fr)
PH (1) PH12006502386B1 (fr)
RU (1) RU2401269C2 (fr)
SG (1) SG127661A1 (fr)
SV (1) SV2006002134A (fr)
TW (1) TW200608979A (fr)
UY (1) UY28931A1 (fr)
WO (1) WO2005121147A1 (fr)
ZA (1) ZA200700011B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
EP1882475A1 (fr) * 2006-07-26 2008-01-30 Novartis AG Méthodes de traitement de maladies médiées par le récepteur du facteur de croissance fibroblastique
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
CA2698795C (fr) 2007-09-10 2016-04-19 Cipla Limited Procede de preparation d'un inhibiteur de la kinase raf et intermediaires utilisables dans ledit procede
KR20100075932A (ko) * 2007-09-25 2010-07-05 바이엘 헬스케어, 엘엘씨 오로라 키나아제의 저해를 통하여 암을 치료하는데 유용한 피롤로트리아진 유도체
EP2085397A1 (fr) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
WO2010071885A1 (fr) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines en tant qu'inhibiteurs d'alk et de jak2
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
SG195100A1 (en) 2011-07-01 2013-12-30 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2862981C (fr) * 2011-12-15 2020-02-25 Bayer Pharma Aktiengesellschaft Benzothienyl - pyrrolotriazines substituees et utilisations de celles-ci pour le traitement du cancer
ES2581065T3 (es) * 2012-02-23 2016-08-31 Bayer Intellectual Property Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
CA2952287C (fr) * 2014-06-17 2023-05-16 Chiesi Farmaceutici S.P.A. Derives d'indolizine utiles en tant qu'inhibiteurs de phosphoinositide 3-kinases
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
EP3394056B1 (fr) 2015-12-22 2021-04-14 Shy Therapeutics LLC Composés pour le traitement du cancer et de maladies inflammatoires
CA3016196A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha a petites molecules
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
WO2018161033A1 (fr) * 2017-03-02 2018-09-07 Wright, Adrian Inhibiteurs ire1-alpha à petites molécules
CA3066939A1 (fr) 2017-06-21 2018-12-27 SHY Therapeutics LLC Composes interagissant avec la superfamille ras destines a etre utilises dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
EP3906029A4 (fr) 2018-12-31 2022-09-21 Biomea Fusion, LLC Inhibiteurs de l'interaction ménine-mll
SI3953357T1 (sl) 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
WO2020231990A1 (fr) * 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Inhibiteurs de fgfr et leurs procédés d'utilisation
JP7353682B2 (ja) * 2019-09-26 2023-10-02 深▲チェン▼市塔吉瑞生物医薬有限公司 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
EP4114401A1 (fr) 2020-03-06 2023-01-11 Incyte Corporation Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2097384C1 (ru) * 1989-10-31 1997-11-27 Биокрист Фармасьютикалз Инк. Производные 2-амино-7-(chr2r3)-3н,5н-пирроло[3,2-d]-пиримидин-4-она, способы их получения и способ селективного ингибирования пролиферации т-лимфоцитов млекопитающего и не оказывающий воздействия на b-лимфоциты
ES2258459T3 (es) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
DK1363910T3 (da) * 2000-11-17 2006-06-26 Bristol Myers Squibb Co Fremgangsmåder til behandling af P39-kinase-associerede tilstande og pyrrolotriazinforbindelser, der er anvendelige som kinase-inhibitorer
US6951859B2 (en) * 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR20100075932A (ko) 2007-09-25 2010-07-05 바이엘 헬스케어, 엘엘씨 오로라 키나아제의 저해를 통하여 암을 치료하는데 유용한 피롤로트리아진 유도체

Also Published As

Publication number Publication date
ZA200700011B (en) 2008-11-26
KR101235602B1 (ko) 2013-02-21
HN2005000255A (es) 2010-09-17
KR20070035028A (ko) 2007-03-29
NO20070049L (no) 2007-01-30
SG127661A1 (en) 2007-01-30
CA2569396A1 (fr) 2005-12-22
EP1765823B1 (fr) 2010-03-31
RU2401269C2 (ru) 2010-10-10
NZ551742A (en) 2010-08-27
PH12006502386B1 (en) 2010-12-23
UY28931A1 (es) 2005-12-30
BRPI0510848A (pt) 2007-11-27
EP1765823A1 (fr) 2007-03-28
HK1109141A1 (en) 2008-05-30
ECSP067043A (es) 2006-12-29
JP2008501703A (ja) 2008-01-24
SV2006002134A (es) 2006-10-04
MXPA06013457A (es) 2007-03-01
GT200500137A (es) 2006-05-18
AR049138A1 (es) 2006-06-28
JP4958772B2 (ja) 2012-06-20
US20130225809A1 (en) 2013-08-29
ES2342722T3 (es) 2010-07-13
WO2005121147A1 (fr) 2005-12-22
CN1993361B (zh) 2010-05-26
DE602005020293D1 (de) 2010-05-12
US8338595B2 (en) 2012-12-25
MX279139B (es) 2010-09-21
IL179264A0 (en) 2007-03-08
CA2569396C (fr) 2011-12-20
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
CN1993361A (zh) 2007-07-04
ATE462708T1 (de) 2010-04-15
PE20060243A1 (es) 2006-04-21
US7563791B2 (en) 2009-07-21
TW200608979A (en) 2006-03-16
AU2005252217A1 (en) 2005-12-22
AU2005252217B2 (en) 2011-05-12
US20070208013A1 (en) 2007-09-06
MY145077A (en) 2011-12-15

Similar Documents

Publication Publication Date Title
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
EP1957077A4 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
EP2096919A4 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
EP1357908A4 (fr) Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
EP1374900A4 (fr) Remedes pour des maladies liees a l'arthrite chronique du nourrisson
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
FR15C0046I2 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
EP1551369A4 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
EP1311261A4 (fr) Medicaments pour le traitement chimiotherapeutique de maladies
EP2120938A4 (fr) Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
EP1644039A4 (fr) Compositions et procedes pour le traitement des troubles lies a la coagulation
EP1816913A4 (fr) Nouveaux composes utiles pour le traitement du cancer et des troubles associes a la fonction d'angiogenese
EP1831385A4 (fr) Enzymes pour le traitement d'amidon
EP1850880A4 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
MA28871B1 (fr) Derives tricycliques accoles pour le traitement de troubles psychotiques
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
MA26951A1 (fr) Derives de pyrazole pour le traitement de maladies virales
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
MA28806B1 (fr) Derives d'arylsulfonylstilbene destines au traitement de l'insomnie et de conditions apparentees
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil